BridgeBio Pharma BBIO Treasury Stock
Treasury Stock at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's treasury stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's treasury stock?
- BridgeBio Pharma (BBIO) reported treasury stock of $405.78M in Q1 2026.
- How has BridgeBio Pharma's treasury stock changed year-over-year?
- BridgeBio Pharma's treasury stock increased by 25.5% year-over-year, from $323.28M to $405.78M.
- What is the long-term trend for BridgeBio Pharma's treasury stock?
- Over 5 years (2020 to 2025), BridgeBio Pharma's treasury stock has grown at a 33.9% compound annual growth rate (CAGR), from $75M to $323.28M.
- What does treasury stock mean?
- The value of shares the company has bought back from the market.
- How do you interpret treasury stock?
- An increase indicates a share buyback program, often used to offset dilution from stock-based compensation or to return capital to shareholders.
- How does treasury stock compare across companies?
- Commonly used by mature companies; less frequent in early-stage R&D-focused biotech firms.